US Patent

US10857159 — Halobetasol foam composition and method of use thereof

Formulation · Assigned to Mayne Pharma LLC · Expires 2036-11-30 · 11y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a composition and method for treating various skin diseases using a foamable formulation of the corticosteroid halobetasol.

USPTO Abstract

The present invention provides a composition and method for treating various skin diseases. The composition is formulated as a foamable composition and includes the corticosteroid halobetasol.

Drugs covered by this patent

halobetasol-propionate (HALOBETASOL PROPIONATE)

Patent Metadata

Patent number: US10857159
Jurisdiction: US
Classification: Formulation
Expires: 2036-11-30
Drug substance claim: No
Drug product claim: Yes
Assignee: Mayne Pharma LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.